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Progress in the Fight Against Multidrug-Resistant Bacteria?
A Review of U.S. Food and Drug Administration–Approved Antibiotics,
2010–2015
Dalia Deak, MPH; Kevin Outterson, LLM, JD; John H. Powers, MD; and Aaron S. Kesselheim, MD, JD, MPH

A weak antibiotic pipeline and the increase in drug-resistant
pathogens have led to calls for more new antibiotics. Eight new
antibiotics were approved by the U.S. Food and Drug Administration (FDA) between January 2010 and December 2015: ceftaroline, ﬁdaxomicin, bedaquiline, dalbavancin, tedizolid, oritavancin, ceftolozane–tazobactam, and ceftazidime–avibactam.
This study evaluates the development course and pivotal trials of
these antibiotics for their innovativeness, development process,
documented patient outcomes, and cost. Data sources were
FDA approval packages and databases (January 2010 to December 2015); the Red Book (Truven Health Analytics); Orange
Book: Approved Drug Products with Therapeutic Equivalence
Evaluations (FDA); and supplementary information from company ﬁlings, press releases, and media reports. Four antibiotics
were approved for acute bacterial skin and skin-structure infection. Seven had similar mechanisms of action to those of previously approved drugs. Six were initially developed by small to
midsized companies, and 7 are currently marketed by 1 of 3
large companies. The drugs spent a median of 6.2 years in clinical trials (interquartile range [IQR], 5.4 to 8.8 years) and 8

A

dvances in the treatment and prevention of infectious diseases, in part due to antibiotic development, are one of the greatest gains in medicine of the
past century (1– 4). Many have identiﬁed the increase in
drug-resistant pathogens as a serious threat in maintaining these gains (5–7). Despite the need for new antibiotics with improved effectiveness to address resistance, many stakeholders have observed that the
antibiotic pipeline is weak (8 –12), although these
claims may be overstated (13). Screening of naturally
occurring compounds and use of advanced platforms
to identify targets have led to few returns in recent decades (14). In addition, numerous large, for-proﬁt pharmaceutical companies have ceased active antibiotic development owing to concerns about returns on
investment and the scientiﬁc challenges in antibiotic
discovery (10, 15, 16).
These developments have led to calls for a variety
of incentives to spur development of new antibiotics,
particularly ones targeting multidrug-resistant, gramnegative bacteria (16 –21). The Generating Antibiotic Incentives Now (GAIN) Act of 2012 awarded qualifying
new products faster review times by the U.S. Food and
Drug Administration (FDA), as well as 5 additional years
of market exclusivity above the approximately 7 years
already guaranteed to new small-molecule drugs (22).
In 2015, the House of Representatives passed the 21st
Century Cures Act, which would permit approval of antimicrobials on the basis of preclinical data and preliminary studies in small numbers of patients (23).

months in FDA review (IQR, 7.5 to 8 months). The median number of patients enrolled in the pivotal trials was 666 (IQR, 553 to
739 patients; full range, 44 to 1005 patients), and median trial
duration was 18 months (IQR, 15 to 22 months). Seven drugs
were approved on the basis of pivotal trials evaluating noninferiority. One drug demonstrated superiority on an exploratory
secondary end point, 2 showed decreased efﬁcacy in patients
with renal insufﬁciency, and 1 showed increased mortality compared with older drugs. Seven of the drugs are substantially
more expensive than their trial comparators. Limitations are that
future research may show beneﬁt to patients, new drugs from
older classes may show superior effectiveness in speciﬁc patient
populations, and initial U.S. prices for each new antibiotic were
obtained from public sources. Recently marketed antibiotics are
more expensive but have been approved without evidence of
clinical superiority.
Ann Intern Med. 2016;165:363-372. doi:10.7326/M16-0291 www.annals.org
For author afﬁliations, see end of text.
This article was published at www.annals.org on 31 May 2016.

There are signs that the antibiotic pipeline may already be improving (13). In 2010, the Infectious Diseases Society of America set a goal for 10 novel antibiotics to reach the U.S. market by 2020 (20). Since then,
the FDA has approved 8 new antibiotics. Regulators
and advocates have celebrated the development and
approval of these antibiotics (24). Does this increase in
approvals represent important progress for patients?
To answer this question, we evaluated the discovery,
development course, pivotal trial results, and costs associated with these new drugs.

METHODS
Data Sources and Searches
For all new antibiotics from January 2010 through
December 2015, we extracted key characteristics from
their approval packages by using the Drugs@FDA database (25–30). We then determined the origins of the
drugs and their development, including their corporate
sponsorship history from company press releases and
other public information.
We next reviewed the major steps in preclinical
and clinical investigational development by collecting
details associated with the FDA-designated “pivotal
trials” used to demonstrate efﬁcacy. Details were
collected from FDA reviews and reports on Clinical
Trials.gov.
We identiﬁed whether the FDA imposed any postapproval study requirements. We extracted postmarket
© 2016 American College of Physicians 363
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commitments or requirements from the FDA's online
database (31) and assessed the status of each as of
December 2015. We extracted postapproval incentives
from the FDA's Orange Book: Approved Drug Products
with Therapeutic Equivalence Evaluations (32) and company press releases.
Finally, to determine the cost of each drug for a
recommended duration of course of treatment, we obtained the average wholesale U.S. price for each new
antibiotic and its clinical trial comparator from the Red
Book (33).
Study Selection
We studied all new molecular entity antibiotics approved by the FDA between January 2010 and December 2015.
Data Synthesis and Analysis
For each drug, we assessed the mechanism of action, larger drug class, year of discovery, and approved
indications. We also identiﬁed in vitro activity against
ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species) (34, 35) and Centers for Disease Control
and Prevention urgent-threat pathogens (Clostridium
difﬁcile, carbapenem-resistant Enterobacteriaceae, and
drug-resistant Neisseria gonorrhoeae [cephalosporin
resistance]) (6), on the basis of information included in
the FDA approval packages. In vitro activity does not
necessarily reﬂect beneﬁts on actual patient clinical
outcomes, as exempliﬁed by such drugs as tigecycline
and doripenem (36, 37).
To determine the corporate sponsorship history of
the antibiotics, we examined the size of the company,
given the different incentives that may be needed for
different-sized companies. We classiﬁed “large companies” as those with more than 10 000 employees and
small to midsized companies as those with 10 000 or
fewer employees.
In assessing pivotal clinical trials for each antibiotic,
we extracted indications, comparator drugs, end
points, trial sizes, trial durations, and trial hypotheses
(noninferiority versus superiority). We tracked primary
end points of the trials, as well as FDA-recommended
secondary end points (for example, a new recommended end point from the guidance document). Because the ceftolozane–tazobactam trials relied on
pooled data, the time for each trial was averaged with
its pooling counterpart.
We determined the length of time each antibiotic
spent in clinical development as the time from investigational new drug (IND) status (the application to begin
human trials) to new drug application (NDA) status (the
sponsor's full submission to FDA). Regulatory review
time ran from the date of NDA submission to FDA approval. We assessed whether each antibiotic qualiﬁed
for special regulatory pathways or designations, including qualiﬁed infectious disease product, fast track, priority review, accelerated approval, breakthrough therapy, and orphan drug designation (see the Appendix,
available at www.annals.org, for deﬁnitions of the pre364 Annals of Internal Medicine • Vol. 165 No. 5 • 6 September 2016
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ceding 6 terms). We also assessed whether each drug
was awarded any postapproval incentives.
To determine the cost of each antibiotic, we calculated a price range on the basis of the overall dose and
duration of the treatment from the average unit price
extracted from the Red Book (33).

RESULTS
The 8 new antibiotics were ceftaroline, ﬁdaxomicin,
bedaquiline, dalbavancin, tedizolid, oritavancin, ceftolozane–tazobactam, and ceftazidime–avibactam. Four
were approved in 2014. Five are administered intravenously and 2 orally, and 1 was approved in both formulations (Table 1).
Mechanisms of Action and Indications
Four drugs were initially indicated for acute bacterial skin and skin-structure infections; 2 for complicated
intra-abdominal infection (CIAI) and complicated urinary tract infection (CUTI); and 1 each for communityacquired pneumonia, C difﬁcile–associated diarrhea,
and multidrug-resistant tuberculosis (Table 1). Three of
the 8 drugs showed in vitro activity against ESKAPE
pathogens; 1 of the drugs, ﬁdaxomicin, demonstrated
in vitro activity against a Centers for Disease Control
and Prevention urgent-threat pathogen, C difﬁcile.
Only bedaquiline was speciﬁcally indicated for a disease due to a multidrug-resistant pathogen, although
most demonstrated in vitro activity against grampositive drug-resistant pathogens (38, 39). For example, although ceftaroline was found to have in vitro activity against methicillin-resistant S aureus (MRSA), the
trials used to support FDA approval for pneumonia did
not speciﬁcally study efﬁcacy in disease due to MRSA.
Still, the drug received an indication for skin infections
due to MRSA (13, 40).
Seven antibiotics fell within established drug
classes, the most common being ␤-lactams (ceftaroline,
ceftolozane–tazobactam, and ceftazidime–avibactam).
The one drug involving a new mechanism of action was
bedaquiline, a diarylquinoline targeting adenosine
triphosphate synthase to inhibit the growth of drugresistant tuberculosis (39).
Drug Development
Six antibiotics were initially developed by small to
midsized companies, and 7 were sponsored by small to
midsized companies at the time of approval (Figure).
Larger manufacturers then became involved after approval: 7 are currently marketed by 1 of 3 large companies. For example, Actavis (~17 000 employees) acquired dalbavancin and ceftazidine–avibactam after
smaller companies had guided these products through
FDA approval. In the case of dalbavancin, Pﬁzer
(~78 000 employees) acquired Vicuron Pharmaceuticals in 2005, but voluntarily withdrew the NDA for dalbavancin. In 2009, Pﬁzer divested Vicuron Pharmaceuticals, with Durata Therapeutics (<100 employees)
subsequently moving the drug through approval. In
2014, Durata Therapeutics was acquired by Actavis,
which then merged with Allergan.
www.annals.org
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Table 1. Antibiotic Drug Details, Development Milestones, and ESKAPE Status
Drug

IND Filed

NDA Filed Approval
Date

Current
Manufacturer

Ceftaroline

December
2004
August
2003

December 29 October
2009
2010
November 27 May 2011
2010

Actavis

Bedaquiline

November
2006

June 2012

Dalbavancin

July 2000

Tedizolid

November
2007;
August
2009
August
1996
July 2009

September 23 May 2014
2013
October
20 June 2014
2013

Fidaxomicin

Oritavancin
Ceftolozane–
tazobactam
Ceftazidime–
avibactam

January
2008

28 December
2012

December
2013
April 2014

6 August
2014
19 December
2014

June 2014

25 February
2015

Drug Class (Year
of Discovery)

Cephalosporin
(1928)
Cubist
Macrolide (1948)
Pharmaceuticals
(subsidiary of
Merck)
Janssen
Diarylquinoline
Research and
(1997)
Development
(Johnson &
Johnson)
Actavis

Lipoglycopeptide
(1953)
Cubist
Oxazolidinone
Pharmaceuticals (1955)
(subsidiary of
Merck)
The Medicines
Glycopeptide
Company
(1953)
Cubist
Cephalosporin
Pharmaceuticals (1928) +
(subsidiary of
␤-lactamase
Merck)
inhibitor
AstraZeneca/
Cephalosporin
Actavis
(1928) +
␤-lactamase
inhibitor

Method of
Administration

Novel
Mechanism
of Action

Indications

In Vitro
Activity
Against
ESKAPE
Pathogens?

Intravenous

No

ABSSSI; CABP

Yes

Oral

No

CDAD and
prevention of
recurrences

No*

Oral

Yes

No†

Intravenous

No

Pulmonary
tuberculosis
caused by
multidrugresistant
tuberculosis
ABSSSI

Oral;
intravenous

No

ABSSSI

No

Intravenous

No

ABSSSI

No

Intravenous

No

CIAI; CUTI

Yes

Intravenous

No

CIAI; CUTI

Yes

No

ABSSSI = acute bacterial skin and skin-structure infection; CABP = community-acquired bacterial pneumonia; CDAD = Clostridium difﬁcile–associated diarrhea; CIAI = complicated intra-abdominal infection; CUTI = complicated urinary tract infection; ESKAPE = Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species; IND = investigational new
drug; NDA = new drug application.
* Clostridium difﬁcile is a Centers for Disease Control and Prevention urgent-threat pathogen.
† Multidrug-resistant tuberculosis is a global health priority.

Development Times
The antibiotics in our cohort spent a median of 6.2
years between IND and NDA status (interquartile range
[IQR], 5.4 to 8.8 years) and a median of 8 months between NDA status and FDA approval (IQR, 7.5 to 8
months) (Table 1). Ceftolozane–tazobactam spent the
shortest time between IND and NDA status (4.8 years).
Oritavancin had the longest development period (17.3
years), which was suspended for multiple years after
initial trial results showed an increased rate of injectionsite inﬂammation and the drug failed to demonstrate
noninferiority in pivotal trials using daily dosing. Later,
Targanta Therapeutics Corporation acquired rights to
the drug and demonstrated that the inﬂammation was
associated with high infusion rates and high drug concentrations, leading to approval for the drug on the
basis of demonstration of noninferiority with weekly
rather than daily dosing. Excluding oritavancin, the median time from IND to NDA status was 5.9 years (IQR,
5.3 to 6.8 years).
Characteristics of Trials Used to Support
Approval
The median number of patients enrolled in the pivotal trials was 666 (IQR, 553 to 739; full range, 44 to
1005). The pivotal trials lasted a median of 18 months
(IQR, 15 to 22 months). As shown in Table 2, the
strength of evidence differed across the drugs. For example, approval of ceftolozane–tazobactam was based
on 1 trial per indication, because data were pooled
from 2 identical trials each for CUTI and CIAI. Assesswww.annals.org

ment of the efﬁcacy of ceftazidime–avibactam was
based on 2 early-phase exploratory trials without prespeciﬁed hypotheses (rather than conﬁrmatory phase 3
trials), along with previous ﬁndings of efﬁcacy and published literature for ceftazidime alone and nonclinical
studies and descriptive data for avibactam. Bedaquiline
was approved on the basis of a phase 2 trial with 2
stages, and an uncontrolled case series (41).
Seven drugs were approved on the basis of pivotal
trials designed with noninferiority hypotheses. All
drugs except for ceftazidime–avibactam had a 10%
noninferiority margin. The 2 early-phase trials for ceftazidime–avibactam did not have prespeciﬁed hypotheses with stated noninferiority margins or inferential statistical testing but were interpreted as demonstrating
noninferiority, allowing large margins of inferiority exceeding 15% to 20%.
Tedizolid was tested based on a noninferiority hypothesis because it was hypothesized, on the basis of
preclinical data, to have fewer adverse effects than linezolid. However, no hypotheses examined patient beneﬁts other than improved effectiveness for any of the
other noninferiority studies, despite beneﬁts other than
improved effectiveness being the primary justiﬁcation
for noninferior efﬁcacy evaluations (42).
The pivotal trials of ﬁdaxomicin showed noninferiority and superiority for effectiveness. Fidaxomicin met
the primary hypothesis of noninferiority to the standard
of care of vancomycin on the primary end point of clinical cure (decreased diarrhea episodes and clinician
Annals of Internal Medicine • Vol. 165 No. 5 • 6 September 2016 365
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Figure. Company sponsorship of antibiotics that were approved by the FDA from 2010 through 2015.

Peninsula

Ceftaroline
(TAK-599, PPI-0903)

Cerexa

J&J

Cerexa, wholly owned by Forest Labs
2010

2004

Cubist

Optimer

Fidaxomicin
(OPT-80, PAR-101)

Actavis

2003

Merck

2011
J&J (Tibotec and Janssen Pharmaceuticals)

Bedaquiline
(TMC207, R207910)

Versicor

Dalbavancin
(BI397)

2012

2006

Blosearch
Italia

(Merger)
Vicuron

Pfizer

2014

2000
Licensed by Trius

Dong A Pharmaceuticals (Korea)
Tedizolid
(TR701)

Oral: 2007
Eli Lilly

Oritavancin
(LY333328)

Actavis

Durata

InterMune

Merck

Cubist

IV: 2009

2014

Voluntary Clinical Hold
Targanta

The Medicines Co.

2014

1996
Cubist

Calixa

Cetolozane–
tazobactam
(CXA-201, FR264205)

2009

2011

AstraZeneca

Novexel SA

Ceftazidime–
avibactam
(NXL104, AVE1330A)

2008

Merck

Actavis

Cerexa
2015

Small or midsized company
Large company
IND application filed
Drug received FDA approval

Company sponsorship timelines and key milestones related to FDA approval are shown. The information in parentheses below each antibiotic is the
name of the drug while under development. FDA = U.S. Food and Drug Administration; IND = investigational new drug; IV = intravenous; J&J =
Johnson & Johnson.

judgment of no need for further antibiotic therapy) at
the end of treatment, on the basis of a 10% margin. It
also demonstrated superiority to the active comparator
in 2 studies for the secondary exploratory end point of
global cure rate—the number of participants in each
treatment group who were considered cured and did
not have a recurrence of diarrhea within 21 days after
the last dose. However, for patients with C difﬁcile–associated diarrhea due to the epidemic BI/NAP1/027
strain, ﬁdaxomicin did not demonstrate superiority in
global cure.
The single trial of ceftolozane–tazobactam in CUTI
was designed with a noninferiority hypothesis but
showed superiority compared with the control drug
levoﬂoxacin on the composite outcome of clinical and
366 Annals of Internal Medicine • Vol. 165 No. 5 • 6 September 2016

microbiological success. Superiority was driven by the
surrogate end point of negative urine cultures in the
subgroups of patients with levoﬂoxacin-resistant organisms. There were no signiﬁcant differences between
ceftolozane–tazobactam and levoﬂoxacin in the direct
patient outcomes of symptoms of urinary tract infection, adverse effects, or deaths, even in the subgroup
with levoﬂoxacin resistance (43). Both ceftolozane–
tazobactam and ceftazidime–avibactam demonstrated
decreased efﬁcacy compared with older control agents
in patients with baseline renal insufﬁciency.
Bedaquiline was the only approved antibiotic in
our study that was tested solely via a superiority hypothesis. A surrogate end point of sputum clearance
was used in the single pivotal trial (41), and bedaquiline
www.annals.org
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Table 2. Characteristics of Pivotal Trials Used to Support FDA Approval of Antibiotics, 2010 –2015
Drug and Trial
Name

Indication

Comparator
Drug

End Point

Analysis Population

Hypothesis

Absolute Risk
Reduction (95%
CI)

Patients Who
Received Drug,
n

Patients in
Comparator
Group, n

MITTE: 6.2% (–0.2%
to 12.5%)
CE: 8.4% (1.4% to
15.4%)
MITTE: 5.9% (–1.0%
to 12.8%)
CE: 5.2% (–2.2% to
12.8%)
MITT: 1.0% (–4.2%
to 6.2%)
CE: –2.2% (–6.6% to
2.1%)
MITT: 0.1% (–4.4%
to 4.5%)
CE: –0.4% (–5.8% to
5.0%)

MITTE: 291
CE: 224

MITTE: 300
CE: 234

Noninferiority
(–10%)

MITTE: 284
CE: 232

MITTE: 269
CE: 214

Noninferiority
(–10%)

MITT: 351
CE: 316

MITT: 347
CE: 347

Noninferiority
(–10%)

MITT: 342‡
CE: 294‡

MITT: 338‡
CE: 292‡

Noninferiority
(–10%)

Ceftaroline
P903-08

CABP

Ceftriaxone

Clinical cure at
test-of-cure*

P903-09

CABP

Ceftriaxone

Clinical cure at
test-of-cure*

P903-06

ABSSSI

Vancomycin +
aztreonam

Clinical cure at
test-of-cure†

P903-07

ABSSSI

Vancomycin +
aztreonam

Clinical cure at
test-of-cure†

Fidaxomicin
101.1.C.003

CDAD

Vancomycin

MITT: 4.2% (–1.4%
to 9.7%)
MITT: 10.2% (2.8%
to 17.5)

MITT: 289

MITT: 307

Noninferiority
(–10%)
Superiority (0%)

101.1.C.004

CDAD

Vancomycin

Clinical cure at
end-of-treatment§
Global cure (cure
response with no
recurrence through
poststudy visit)
Clinical cure at
end-of-treatment§
Global cure (cure
response with no
recurrence through
post-study visit)

MITT: 0.2% (–5.9%
to 6.4%)
MITT: 13.4% (5.4 to
21.1)

MITT: 253

MITT: 256

Noninferiority
(–10%)
Superiority (0%)

Pulmonary TB
caused by
MDR-TB

Placebo with
background
regimen

Time to sputum culture
conversion (2
consecutive negative
cultures from sputa
collected at least 25 d
apart)

MITT: 21

MITT: 23

Exploratory

Pulmonary TB
caused by
MDR-TB

Placebo with
background
regimen

Time to sputum culture
conversion (2
consecutive negative
cultures from sputa
collected at least 25 d
apart)

Culture conversion
rates to MITT:
Week 8: 38.9%
(12.3% to 63.1%)
Week 24: 14.8%
(–11.9% to 41.9%)
Final treatment
success: 4.6%
(–25.5% to 34.1%)
MITT: median: 83 d
(56 to 97 d)
Placebo: median,
125 d (98 to
168 d)

MITT: 79

MITT: 81

Superiority
based on
surrogate
end point

ABSSSI

Vancomycin or
linezolid

Early response at 48–72 h
(spread cessation,
absence of fever)
Reduction in lesion area
from baseline at
48–72 h
Early response at 48–72 h
(spread cessation,
absence of fever)
Reduction in lesion area
from baseline at
48–72 h

ITT: 1.5% (–4.6% to
7.9%)

ITT: 288

ITT: 285

Noninferiority
(–10%)

ITT: 371

ITT: 368

Noninferiority
(–10%)

Early clinical response
(spread cessation) at
48–72 h
≥20% reduction in
primary lesion with no
fever
Early clinical response
(≥20% reduction in
primary lesion) at
48–72 h

ITT: 0.1% (–6.1% to
6.2%)

ITT: 332

ITT: 335

Noninferiority
(–10%)

ITT: 2.6% (–3.0% to
8.2%)

ITT: 332

ITT: 334

Noninferiority
(–10%)

MITT: 3.7% (–1.4%
to 8.7%)

MITT: 473

MITT: 481

Noninferiority
(–10%)

MITT: 503

MITT: 502

Noninferiority
(–10%)

Bedaquiline
C208 stage 1

C208 stage 2

Dalbavancin
DUR001-301

DUR001-302

Tedizolid
TR701-112

TR701-113

ABSSSI

ABSSSI

Vancomycin or
linezolid

Linezolid

ABSSSI

Linezolid

Oritavancin
SOLO1

ABSSSI

Vancomycin

Clinical response (spread
cessation, no fever, no
rescue antibiotic)
≥20% reduction in lesion

SOLO2

ABSSSI

Vancomycin

Clinical response (spread
cessation, no fever, no
rescue antibiotic)
≥20% reduction in lesion

ITT: –1% (–5.7% to
4.0%)
ITT: –1.5% (–7.4% to
4.6%)
ITT: 1.7% (–3.2% to
6.7%)

ITT: 1.9% (–4.5% to
8.3%)

MITT: 3.94%
(–0.59% to 8.47%)
MITT: –2.8% (–7.5%
to 2.0%)
MITT: 0.6% (–3.7%
to 5.0%)

Continued on following page
www.annals.org
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Table 2—Continued
Drug and Trial
Name

Ceftolozane–
tazobactam
CXA-CUTI10-04 and
10-05

CXA-CIAI-1008 and
10-09
Ceftazidime–
avibactam
NXL104/
2001

NXL104/
2002

Indication

Comparator
Drug

CUTI

Levoﬂoxacin

CIAI

Meropenem

CUTI when
limited
or no
treatment
options are
available

Imipenem–
cilastatin

CIAI, in
Meropenem
combination
with
metronidazole
when
limited or
no
treatment
options are
available

End Point

Analysis Population

Hypothesis

Absolute Risk
Reduction (95%
CI)

Patients Who
Received Drug,
n

Patients in
Comparator
Group, n

Composite clinical and
microbiological cure
at test-of-cure
(investigator judgment
that symptoms had
resolved and
microbiological
eradication of the
causative pathogen)
Clinical response at
test-of-cure†

Microbiological
MITT: 8.5%
(2.31% to
14.57%)

Microbiological
MITT: 398

Microbiological
MITT: 402

Noninferiority
(–10%)

Microbiological ITT:
–4.6% (–9.4% to
0.1%)

Microbiological
ITT: 389

Microbiological
ITT: 417

Noninferiority
(–10%)

Microbiological response
(reduction of the
baseline uropathogen
at entry from >105
CFU/mL to <104
CFU/mL)
Clinical and
microbiological
response (cure +
eradication)
Clinical response (clinical
cure: complete
resolution or signiﬁcant
improvement in
symptoms of index
infection with no further
therapy needed;
eradication presumed
with favorable clinical
response)

ME: –1.1% (–27.2%
to 25.0%)

ME: 27

ME: 35

No prespeciﬁed
hypotheses,
but results
interpreted at
noninferiority

Microbiological
MITT: 12% (–9.1%
to 31.7%)

Microbiological
MITT: 46

Microbiological
MITT: 49

ME: –2.2% (–20.4%
to 12.2%)
Microbiological
MITT: –6.4%
(–18.0% to 5.2%)

ME: 68
Microbiological
MITT: 85

ME: 76
Microbiological
MITT: 89

No prespeciﬁed
hypotheses,
but results
interpreted as
noninferiority

ABSSSI = acute bacterial skin and skin-structure infection; CABP = community-acquired bacterial pneumonia; CDAD = Clostridium difﬁcile–associated diarrhea; CE = clinically evaluable; CFU = colony-forming units; CIAI = complicated intra-abdominal infection; CUTI = complicated urinary tract
infection; FDA = U.S. Food and Drug Administration; ITT = intention to treat; MDR-TB = multidrug-resistant tuberculosis; ME = microbiologically
evaluable; MITT = modiﬁed intention to treat; MITTE = modiﬁed intention to treat efﬁcacy; TB = tuberculosis.
* Total resolution of symptoms, or improvement with absence of fever such that no additional antibiotics necessary.
† Total resolution of all signs and symptoms, or improvement such that no additional antibiotics necessary.
‡ Data from reference 40.
§ No further therapy 2 d after completion; 3 or fewer unformed stools for 2 consecutive d and remained well before discontinuation; or marked
reduction in number of unformed stools, with residual abdominal discomfort deemed as recovering bowel, provided no further therapy required.

showed 79% clearance versus 58% at 24 weeks in the
standard-of-care group, although the difference was
not signiﬁcant at later time points. However, incidence
of death, generally from tuberculosis, increased 5-fold
among patients randomly assigned to the experimental
group compared with those assigned to receive standard treatment (45).
Most of the primary and key secondary end points
examined in the trials were clinical “cures” and “responses” based on subjective clinician judgments of
unclearly deﬁned composites of signs, symptoms, and
laboratory values or radiologic results. For example, in
the case of ﬁdaxomicin, a component of the end point
of interest was clinician judgments on need for additional antibiotics for C difﬁcile (46). Exceptions included
the bedaquiline trials (sputum clearance surrogate);
CUTI studies that used a composite of “clinical” and
microbiological outcomes of urine cultures; and acute
bacterial skin and skin-structure infection trials for dalbavancin, tedizolid, and oritavancin (the well-deﬁned
clinician-reported outcome of ≥20% reduction in lesion
size in addition to clinical cure or response). None used
patient mortality or direct measures of patient disability
as primary end points.
368 Annals of Internal Medicine • Vol. 165 No. 5 • 6 September 2016

Regulatory Review Characteristics
Each of the 8 antibiotics received at least 1 expedited drug development or FDA review designation.
All 8 were fast-tracked, and 7 received priority review.
For the most recent 5 antibiotics, the fast-track status
and priority review were conferred on the basis of the
drugs receiving the qualiﬁed infectious disease product designation. Bedaquiline also received accelerated
approval. Four of the drugs— dalbavancin, tedizolid, oritavancin, and ceftolozane/tazobactam—were awarded
additional market exclusivity through the GAIN Act.
One drug, bedaquiline, was awarded orphan drug
status and earned its manufacturer a priority review
voucher—an incentive created to reward sponsors for
developing drugs to treat neglected diseases.
Postmarket Commitments
and Requirements
Among the associated postmarket commitments
and requirements (Appendix Table 1, available at www
.annals.org), the development of bacterial resistance
over 5 years after introduction of the drug to the market
(using in vitro data alone without a requirement for corwww.annals.org
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relation with patient outcomes) had to be assessed for
all 8 drugs, and tests in pediatric populations were required for all drugs except bedaquiline. Three drugs
had additional postmarket requirements intended to
clarify safety and efﬁcacy questions: worse outcomes
noted for ceftazidime–avibactam compared with the
standard of care among patients with baseline renal
impairment; the pharmacokinetics of oritavancin in
patients with severe hepatic or renal impairment, particularly during coadministration of narrow therapeutic
index drugs (such as warfarin); and assessment of longterm outcomes of failure or relapse or death for bedaquiline. Johnson & Johnson was also required to
conduct a follow-up trial conﬁrming the efﬁcacy of bedaquiline because of its accelerated approval based on
a surrogate end point, but was given until 2022 to complete it. A trial to answer the question of whether the
surrogate end point of sputum culture conversion leads
to direct patient beneﬁts, such as improved survival,

had not been initiated as of April 2016, according to
ClinicalTrials.gov.
Duration of Treatment and Drug Prices
The duration of treatment ranged from a single
dose, in the case of oritavancin, to 24 weeks, in the case
of bedaquiline. Prices (Table 3 and Appendix Table 2,
available at www.annals.org) ranged from $1195 to
$4183 (4 to 14 days of ceftolozane–tazobactam for
CIAI) to $36 000 (24 weeks of bedaquiline). With the
exception of tedizolid, these prices are much higher
than those of the comparator drugs— usually generics—
used in the pivotal trials (33).

DISCUSSION
We found that most new antibiotics were additions
to existing drug classes, and half were for the same
indication. Recently added incentives for antibiotic de-

Table 3. Dose, Duration, and Cost of Antibiotic Drugs and Trial Comparators
New Antibiotic

Comparator

Cost Ratio

Drug

Dose and
Duration

Cost Range, $*

Drug

Dose and Duration

Cost Range, $*

Ceftaroline

CABP: 600 mg
every 12 h for
5–7 d
ABSSSI: 600 mg
every 12 h for
5–14 d

CABP:
1666.30–2332.82

CABP: ceftriaxone

CABP: 1 g of ceftriaxone
once daily for 5–7 d

CABP: 9.00–329.35

CABP: 185:1 to
7:1

ABSSSI:
1666.30–4665.64

ABSSSI: vancomycin +
aztreonam

ABSSSI: 470.10–1681.68

ABSSSI: 4:1 to
3:1

200 mg twice
daily for 10 d
400 mg daily for
2 wk, then 200
mg 3 times/wk
for 22 wk

3969.20

Vancomycin†

1252.00–1392.00

3:1

36 000.12

–‡

–‡

Dalbavancin

1 dose of 1000
mg, then 500
mg 8 d later

5364.00

Placebo (both groups
received a
background
multidrug anti–TB
treatment regimen)
Vancomycin or
linezolid

ABSSSI: 1 g of
vancomycin twice daily
and 1 g of aztreonam
twice daily for 5–14 d
125-mg capsule 4 times
daily for 10 d
–‡

Vancomycin:
44.82–574.56
Linezolid: 2938.72

Vancomycin:
120:1 to 9:1
Linezolid: 2:1

Tedizolid

200 mg once
daily for 6 d
1200 mg dose
administered
by IV once
CUTI: 1.5 g
every 8 h for
7d
CIAI:1.5 g every
8 h for 4–14 d
CUTI: 2.5 g
every 8 h for
7–14 d

Oral: 2124
IV: 1692
3480.00

Linezolid

1 g of vancomycin twice
daily for 3–14 d, with
optional switch to 600
mg of linezolid twice
daily for 8 d
600 mg twice a day for
10 d
1 g every 12 h for 7–10 d

3673.40

Oral: 0.5:1
IV: 0.5:1
33:1 to 9:1

CUTI: 2091.60

CUTI: levoﬂoxacin

CIAI:
1195.20–4183.20
CUTI: 7182–14 364

CIAI: meropenem

Fidaxomicin
Bedaquiline

Oritavancin

Ceftolozane–
tazobactam

Ceftazidime–
avibactam

CIAI: 2.5 g every
8 h for 5–14 d
+ MTZ

CIAI: 5130–14 364

Vancomycin

CUTI: imipenem–
cilastatin

CIAI: meropenem

CUTI: 750 mg
levoﬂoxacin daily for
7d
CIAI: 1 g of meropenem
every 8 h for 4–10 d
CUTI: 500 mg
imipenem–cilastatin
every 6 h for 7–14 d
(optional switch to
ciproﬂoxacin after 4 d)
CIAI: 1 g of meropenem
every 8 h for 5–14 d

104.58–410.40

CUTI: 0.35–0.70

CUTI: 5976:1 to
2988:1

CIAI: 154.20–2111.10

CIAI: 8:1 to 2:1

CUTI: 352.80–1680.00

CUTI: 20:1 to
9:1

CIAI: 192.75–2955.54

CIAI: 27:1 to
5:1

ABSSSI = acute bacterial skin and skin-structure infection; CABP = community-acquired bacterial pneumonia; CIAI = complicated intra-abdominal
infection; CUTI = complicated urinary tract infection; IV = intravenous; MTZ = metronidazole; TB = tuberculosis.
* Based on reference 33.
† Although the ﬁdaxomicin trials used oral vancomycin (cost shown here), some providers may compound generic IV into oral administration,
greatly reducing the cost.
‡ Background multidrug anti-TB regimen varied by individual. Possible drugs included ethionamide, kanamycin, oﬂoxacin, pyrazinamide, and
terizidine (all off-patent).
www.annals.org

Annals of Internal Medicine • Vol. 165 No. 5 • 6 September 2016 369

MEDICINE AND PUBLIC ISSUES
velopment have not yet led to new products with improved outcomes in patients with disease due to critical
resistant pathogens at the time of approval, such as
ESKAPE pathogens (35). Although the Infectious Diseases Society of America's goal of 10 new antibiotics
approved by 2020 is likely to be met (20, 35, 38), recently approved antibiotics have generally been lacking in biological innovation or public health importance
(47).
One major exception was bedaquiline, which was
developed to treat a pressing global public health priority in multidrug-resistant tuberculosis. Yet, even for
bedaquiline, the clinical trials results show increased
mortality and its initial impact has been limited owing
to its lack of availability and lack of data on its use (48).
Postmarket commitments for this product remain in
progress, a ﬁnding consistent with current limitations in
our ability to conduct timely postmarket oversight of
drugs approved via expedited pathways (49).
We also found important deﬁciencies in the clinical
trials leading to approval of these new antibiotic products. First, because most pivotal trial designs were primarily noninferiority trials, the antibiotics were not studied to evaluate whether they have substantial beneﬁts
in efﬁcacy over what is currently available. None of the
drugs demonstrated superior outcomes on patient
survival or disability in their pivotal trials despite promising in vitro, animal, and pharmacokinetic data. For
example, the apparent superiority of ceftolozane–
tazobactam was based on a surrogate end point of
negative urine cultures, and bedaquiline worsened survival despite positive results on a surrogate end point.
Second, none of the trials evaluated direct patient
outcomes as primary end points. Clinical cure and response end points examined in these trials were based
on clinician judgments of a composite of signs, symptoms, or laboratory tests, sometimes with no clear definition of what was measured or how clinicians were to
gauge success. In the trials of dalbavancin, oritavancin,
and tedizolid, the primary end point of clinical response was cessation of spread of the baseline lesion,
absence of fever, and no rescue antibiotic medication,
none of which are direct measures of patient survival or
disability (50 –52).
Finally, some drugs did not have conﬁrmatory evidence from a second independent trial or did not have
any conﬁrmatory trials (as was the case for ceftazidime–
avibactam). The FDA has traditionally preferred 2 trials
per indication because the results of any single trial
“may be subject to unanticipated, undetected systematic biases” or occur by chance alone (53), although
approval on the basis of a single pivotal trial occurred
about one third of the time in a recent review. Continued monitoring and evidence generation are still
needed for these antibiotics to ensure demonstration
of their efﬁcacy in relevant populations and resistance
proﬁles related to patient outcomes moving forward
(49).
Despite unclear evidence of additional beneﬁt,
most of these drugs have been priced at a premium.
Yet, none of these antibiotics have attained substantial
370 Annals of Internal Medicine • Vol. 165 No. 5 • 6 September 2016
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sales since their approval. Ceftaroline, for example, recorded $13.1 million in sales in 2013 (54). One reason
could be the poor clinical evidence supporting their
use; private payers have sometimes resisted reimbursing high-priced new drugs without solid underlying evidence of additional beneﬁts over available lowerpriced therapies (even if the FDA does not require such
evidence for approval). For example, the Centers for
Medicare & Medicaid Services refused to grant additional reimbursement to dalbavancin under the new
technology add-on payment program, which is designed to support timely access to important but potentially costly new therapies, owing to the absence of
evidence demonstrating superiority or that improved
convenience affected patient-centered outcomes (16).
Our data show that the FDA is efﬁciently approving
new antibiotics. The FDA review time was shorter than
for small-molecule anti-infective drugs approved in
previous years (55). Antibiotic clinical trials are also
speedy. The length of the pivotal clinical trials—which
are supposed to be the longest and most detailed evaluation of a drug—was consistent with or was even
shorter than that for other drugs (56). Finally, the number of patients enrolled in antibiotic pivotal trials historically has been smaller compared with other therapeutic areas (56). These data undermine the claim that
clinical development of antibiotics is unreasonably burdensome (57, 58).
Despite the ease of testing and approving new antibiotics, research and development is still largely being driven outside of the major pharmaceutical manufacturers. Financial incentives tailored to small or
midsized companies may therefore be most effective in
leading to new innovation. Some examples that have
been offered include transferrable tax credits, generous patent buyouts, and prizes (59). Such ﬁnancial incentives could also be tailored to ensure that they apply only to novel therapies directed at infections of
particular public health importance. The upfront investment needed in the ﬁeld of antibiotics also may not be
as high as expected; indeed, a recent model of antibiotic drug development assumed longer review times
and longer clinical development times than we report
here (59).
Our study has limitations. First, future research may
show that these new antibiotics could offer substantial
beneﬁts to patients—for example, in terms of dosing
convenience facilitating earlier discharge from
hospitals— even though such data were lacking at the
time of approval. Second, new drugs from older classes
may show superior effectiveness over older drugs in
the same class in speciﬁc patient populations. Finally,
we obtained the initial U.S. price for each new antibiotic
from public sources, as opposed to the manufacturers
of the drugs. This does not allow us to adequately account for differences in negotiated rates associated
with public and private payers.
In conclusion, we found that recent antibiotic development activity has been impressive in terms the
quantity of antibiotics developed and approved for
marketing, but does not constitute a substantial imwww.annals.org
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provement in terms of quality in clinical practice on patient outcomes. A range of regulatory and other incentives have targeted antibiotic development, and the
FDA has demonstrated efﬁciency in approving antibiotics. However, many of the drugs in our cohort were
approved for the same indication, only 1 was ﬁrst in
class, and numerous deﬁciencies were identiﬁed in the
clinical trial evidence collected at the time of approval.
Only 1 drug was studied in patients with multidrugresistant disease. As antibiotic innovation continues to
move forward, greater attention needs to be paid to
incentives for developing high-quality new products
with demonstrated superiority to existing products on
outcomes in patients with multidrug-resistant disease,
replacing the current focus on quantity and presumed
future beneﬁts.
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APPENDIX: DEFINITIONS OF FDA-EXPEDITED
DEVELOPMENT OR REVIEW PROGRAMS
Accelerated approval allows approval to be based
on a surrogate end point or an intermediate clinical
end point that is reasonably likely to predict a drug's
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clinical beneﬁt on how patients feel, function, or survive
(60).
Breakthrough therapy offers increased resources
and cross-disciplinary attention within the FDA that are
intended to speed development (60).
Fast track affords the sponsor frequent interactions
with the FDA review team and the promise of more
efﬁcient review, if the FDA determines that the product
for life-threatening disease may be effective and may
have added beneﬁts over available therapies after preliminary evaluation of the clinical data (60).
Orphan drug status provides a sponsor with tax
breaks, access to special grant funding, waiver of regulatory fees, and 7 years of market exclusivity after approval (61).
Priority review guarantees initial FDA review within
6 months instead of the standard 10-month deadline
(60).
Qualiﬁed infectious disease product designation,
available since 2012, is made before any clinical data
are available. It provides incentives that include the
prospect of a shorter preapproval development period,
automatic priority review, and a 5-year extension of exclusivity after approval. Unlike the standard fast track,
the new drug does not need to have promise of added
beneﬁts (22).
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Appendix Table 1. Postmarket Commitments and Requirements as of December 2015*
Drug

PMR/Commitment (Status†)

Ceftaroline fosamil

1. Perform a trial in pediatric patients being treated concomitantly with antibacterial agent(s) to evaluate single-dose
pharmacokinetic parameters and assess safety of Teﬂaro (ceftaroline fosamil) in all pediatric age groups. Required under
PREA (fulﬁlled)
2. Perform a randomized comparison of Teﬂaro (ceftaroline fosamil) and comparator in pediatric patients with CABP utilizing
an enrichment strategy for enrollment of patients with MRSA. Pediatric patients aged <17 y with CABP must be enrolled,
with a minimum of 150 patients receiving Teﬂaro (ceftaroline fosamil). Required under PREA (submitted)
3. Perform a randomized comparison of Teﬂaro (ceftaroline fosamil) and comparator in pediatric population with ABSSSI,
including patients with infection suspected or demonstrated to be caused by MRSA. Pediatric patients aged <17 y with
ABSSSI must be enrolled, with a minimum of 150 patients receiving Teﬂaro (ceftaroline fosamil). Required under PREA
(submitted)
4. Perform a trial assessing the CSF concentration proﬁle of Teﬂaro (ceftaroline fosamil) in infants aged <2 mo. A minimum of
12 infants aged <2 mo receiving antibacterials for treatment of late-onset neonatal sepsis must be studied. Required
under PREA (pending)
5. Perform a randomized comparison of Teﬂaro (ceftaroline fosamil) and comparator in infants aged <2 mo with ABSSSI and
CABP, including patients with infections suspected or demonstrated to be caused by MRSA. Required under PREA
(pending)
6. Conduct a prospective study over a 5-y period after introduction of Teﬂaro (ceftaroline fosamil) to the market to determine
whether decreased susceptibility to Teﬂaro (ceftaroline fosamil) is occurring in the target bacteria included in the
Indications section of the approved Teﬂaro (ceftaroline fosamil) package insert. Provide a detailed protocol describing the
study to the FDA for review and comment before commencing the study. Required under FDAAA (ongoing)
1. Conduct a prospective clinical trial of 10 d of Diﬁcid (ﬁdaxomicin) in at least 32 pediatric patients (aged 6 mo to <18 y) with
Clostridium difﬁcile–associated diarrhea to evaluate the safety and pharmacokinetics (including serum and fecal
concentrations) of Diﬁcid (ﬁdaxomicin). Required under PREA (fulﬁlled)
2. Conduct a prospective, randomized clinical trial to demonstrate safety and effectiveness of Diﬁcid (ﬁdaxomicin) compared
with vancomycin in pediatric patients (aged 6 mo to <18 y) with C difﬁcile–associated diarrhea. Required under PREA
(pending)
3. Conduct a prospective study over a 5-y period after introduction of Diﬁcid (ﬁdaxomicin) to the market to determine
whether decreased susceptibility to Diﬁcid (ﬁdaxomicin) is occurring in C difﬁcile. Provide a detailed protocol describing
the study to the FDA for review and comment before commencing the study. Required under FDAAA (ongoing)
4. Conduct a prospective, randomized, comparative trial to demonstrate the efﬁcacy of Diﬁcid (ﬁdaxomicin) in the treatment
of patients with multiple recurrences of C difﬁcile associated diarrhea (pending)
1. Conduct a conﬁrmatory randomized, double-blind, placebo-controlled, multicenter, phase 3 trial in persons with sputum
smear–positive pulmonary MDR-TB. This trial should assess long-term outcomes of failure or relapse or death ≥6 mo after
all MDR-TB treatment is completed. Required under accelerated approval (ongoing) [Note: Described as “ongoing” in the
FDA database, but not listed as under way on ClinicalTrials.gov]
2. Develop a patient registry for bedaquiline-treated patients to assess incidence rates of serious adverse events, including
death. Required under FDAAA (pending)
3. To inform PMR 5, conduct a study to deﬁne the quality control ranges of bedaquiline for MDR-TB isolates using standard
proportion methods. Required under FDAAA (fulﬁlled)
4. To inform PMR 5, conduct a study to deﬁne the quality control ranges of bedaquiline for MDR-TB isolates using MIC
methods. Required under FDAAA (fulﬁlled)
5. Conduct a prospective in vitro study over a 5-y period after introduction of Sirturo (bedaquiline) to the market to
determine MICs of MDR-TB isolates to bedaquiline for the ﬁrst 5 y from marketing. Report interpretation of these MICs
once additional quality control testing methods are developed as noted in the required postmarketing studies for PMRs 3
and 4. Provide a detailed protocol describing the study to the FDA for review and comment before commencing the
study. Required under FDAAA (pending)
6. Conduct an in vitro study to characterize the potential of bedaquiline and M2 as a substrate, inhibitor or inducer of the
OATP1B1 and OATP1B3 drug transporters. Required under FDAAA (fulﬁlled)
8. Submit ﬁnal study report and electronic data for Study C208 Stage II (fulﬁlled)
9. Submit ﬁnal study report and electronic data for Study C209 (fulﬁlled)
1. Conduct a single-dose pharmacokinetic study in children aged 3 mo to <12 y. Required under PREA (ongoing)
2. Conduct a single-dose pharmacokinetics study in neonates/infants aged 0 to <3 mo. Required under PREA (pending)
3. Conduct a phase 3, randomized, comparator-controlled study of dalbavancin in children aged 3 mo to 17 y with ABSSSI.
Required under PREA (pending)
4. Conduct a phase 3, randomized, comparator-controlled study of dalbavancin in neonates/infants from birth to age <3 mo
with ABSSSI. Required under PREA (pending)
5. Conduct U.S. surveillance studies for 5 y from the date of marketing Dalvance to determine whether resistance to
dalbavancin has developed in those organisms speciﬁc to the indication in the label for ABSSSI. Required under FDAAA
(pending)
6. Conduct studies to deﬁne the mechanism(s) of resistance for isolates identiﬁed as being resistant to dalbavancin during
the surveillance period (5 y from the date of marketing). Required under FDAAA (pending)
9. Conduct an in vitro study evaluating interactions between dalbavancin hydrochloride and coagulation tests. Required
under FDAAA (pending)
1. Conduct a randomized, single-blind, multicenter safety and efﬁcacy study of intravenous to oral Sivextro (tedizolid
phosphate) and intravenous to oral comparator for the treatment of acute bacterial skin and skin structure infections in
pediatric patients aged 12 to <18 y. Required under PREA (pending)
2. Conduct a randomized, single-blind, multicenter safety and efﬁcacy study of intravenous to oral Sivextro (tedizolid
phosphate) and intravenous to oral comparator for the treatment of acute bacterial skin and skin structure infections in
pediatric patients aged >3 mo to <12 y. Required under PREA (pending)
3. Conduct an open-label, multicenter study of 10-14 d of IV Sivextro (tedizolid phosphate) for hospital-acquired late-onset
sepsis in full-term and preterm neonates and infants aged 5 d to <3 mo. Required under PREA (pending)

Fidaxomicin

Bedaquiline

Dalbavancin

Tedizolid

Continued on following page
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Appendix Table 1—Continued
Drug

Oritavancin

Ceftolozane–tazobactam

Ceftazidime–avibactam

PMR/Commitment (Status†)
4. Conduct a phase 1 single-dose safety and pharmacokinetic study of oral and IV Sivextro (tedizolid phosphate) in patients
aged 2 y to <12 y. Required under PREA (pending)
5. Conduct a phase 1 single-dose safety and pharmacokinetic study of oral and intravenous Sivextro (tedizolid phosphate) in
inpatients aged <2 y. Required under PREA (pending)
6. Conduct U.S. surveillance studies for 5 y from the date of marketing Sivextro to determine whether resistance to tedizolid
has developed in those organisms speciﬁc to the indication in the label for ABSSSI. Required under FDAAA (pending)
1. Conduct an open-label, dose-ﬁnding, pharmacokinetics, safety, and tolerability study of Orbactiv (oritavancin
diphosphate) single-dose infusion in pediatric patients aged <18 y with suspected or conﬁrmed bacterial infections.
Required under PREA (pending)
2. Conduct a multicenter, evaluator-blinded, randomized study to evaluate the safety and tolerability of single-dose IV
Orbactiv (oritavancin diphosphate) versus vancomycin for the treatment of pediatric patients aged <18 y with ABSSSI.
Required under PREA (pending)
3. Conduct a U.S. surveillance study over a 5-y period from the date of marketing Orbactiv (oritavancin diphosphate) to
determine whether resistance to oritavancin has developed in those organisms speciﬁc to the indication in the label for
ABSSSI. Required under FDAAA (pending)
4. Conduct an open-label trial evaluating the safety of a single 1200 mg IV dose of Orbactiv (oritavancin diphosphate) in
patients on concomitant chronic warfarin therapy who are being treated for ABSSSI. Required under FDAAA (pending)
5. Conduct an open-label trial to assess the clinical signiﬁcance of the drug–drug interaction between a single 1200-mg IV
dose of Orbactiv (oritavancin diphosphate) and warfarin in healthy volunteers. Required under FDAAA (pending)
6. Conduct a single-center, open-label trial to evaluate the effects of a single 1200-mg IV dose of Orbactiv (oritavancin
diphosphate) on the results of multiple coagulation tests in healthy volunteers. Required under FDAAA (pending)
7. Conduct a study to evaluate the effects of oritavancin on phospholipid- and non–phospholipid-based coagulation tests in
vitro. Required under FDAAA (pending)
1. Conduct a randomized, double-blind, multicenter, comparative study to establish the safety and tolerability proﬁle of
ceftolozane–tazobactam compared with that of meropenem in hospitalized children from birth to age <18 y with CUTI. The
dose for this study will be determined upon review of the data to be submitted by December 2016 from a single-dose,
multicenter, noncomparative study assessing the pharmacokinetics of ceftolozane–tazobactam in pediatric patients ages 0
to <18 y that was initiated in June 2014. Required under PREA (pending)
2. A randomized, double-blind, multicenter, comparative study to establish the safety and tolerability proﬁle of
ceftolozane–tazobactam compared with that of meropenem in hospitalized children from birth to age <18 y with CIAI. The
dose for this study will be determined upon review of the data to be submitted by December 2016 from the single-dose,
multicenter, noncomparative study assessing the pharmacokinetics of ceftolozane–tazobactam in pediatric patients aged 0
to <18 y that was initiated in June 2014. Required under PREA (pending)
3. Conduct a prospective study over a 5-y period after the introduction of Zerbaxa (ceftolozane–tazobactam) to the market to
determine whether decreased susceptibility to Zerbaxa (ceftolozane–tazobactam) is occurring in the target population of
bacteria that are in the approved Zerbaxa (ceftolozane–tazobactam) label. Required under FDAAA (pending)
1. Conduct a randomized, multicenter, active-controlled trial to evaluate the safety and tolerability of Avycaz
(ceftazidime–avibactam) in children aged 3 mo to <18 y with CUTI. The dose for this study will be determined upon review
of the data to be submitted by June 2015 from a single-dose, multicenter, noncomparative study assessing the
pharmacokinetics of Avycaz (ceftazidime–avibactam) in pediatric patients aged 3 mo to <18 y. Required under PREA
(pending)
2. Conduct a randomized, multicenter, active-controlled trial to evaluate the safety and tolerability of Avycaz
(ceftazidime–avibactam) in children aged 3 mo to <18 y with CIAI. The dose for this study will be determined upon review
of the data to be submitted by June 2015 from a single-dose, multicenter, noncomparative study assessing the
pharmacokinetics of Avycaz (ceftazidime–avibactam) in pediatric patients aged 3 mo to <18 y. Required under PREA
(pending)
3. Conduct a trial to evaluate the pharmacokinetics, safety, and tolerability of Avycaz (ceftazidime–avibactam) in children from
birth to age <3 mo with late-onset sepsis. Required under PREA (pending)
4. Conduct a prospective study over a 5-y period after the introduction of Avycaz (ceftazidime–avibactam) to the market to
determine whether decreased susceptibility to Avycaz (ceftazidime–avibactam) is occurring in the target population of
bacteria that are in the approved Avycaz (ceftazidime–avibactam) label. Required under FDAAA (pending)
5. Conduct a trial or submit data from the phase 3 trial in CIAI to evaluate the pharmacokinetics, safety, and clinical outcomes
in adult patients with baseline renal impairment (creatinine clearance ≤50 mL/min) receiving Avycaz (ceftazidime–
avibactam) dosing regimens adjusted for renal function. Required under FDAAA (ongoing)

ABSSSI = acute bacterial skin and skin-structure infection; CABP = community-acquired bacterial pneumonia; CIAI = complicated intra-abdominal
infection; CSF = cerebrospinal ﬂuid; CUTI = complicated urinary tract infection; FDA = U.S. Food and Drug Administration; FDAAA = FDA
Amendments Act; IV = intravenous; MDR-TB = multidrug-resistant tuberculosis; MIC = minimum inhibitory concentration; MRSA = methicillinresistant Staphylococcus aureus; PREA = Pediatric Research Equity Act; PMR = postmarket requirement.
* Some numbers are not listed because they were not found in the FDA database.
† Pending: The study has not been initiated (i.e., no participants have been enrolled or animals dosed), but does not meet the criterion for delayed
(i.e., the original projected date for initiation of patient accrual or initiation of animal dosing has not passed). Ongoing: The study is proceeding
according to, or is ahead of, the original schedule. Delayed: The progression of the study is behind the original study schedule. Terminated: The
applicant ended the study before completion, and has not yet submitted a ﬁnal study report to the FDA. Submitted: The applicant has concluded
or terminated the study and has submitted a ﬁnal study report to the FDA, but FDA has not yet notiﬁed the applicant in writing that the study
commitment has been fulﬁlled or that the commitment has been released. Fulﬁlled: The applicant has submitted the ﬁnal study report for the
commitment, and upon review of the ﬁnal study report, FDA is satisﬁed that the applicant has met the terms of the commitment. Released: FDA has
informed the applicant that it has been released from its obligation to conduct the postmarketing study because the study is either no longer
feasible or would no longer provide useful information.
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200 mg twice daily
for 10 d
400 mg daily for 2
wk, then 200 mg 3
times/wk for 22 wk

One dose of 1000
mg ,then 500 mg
8 d later

200 mg once daily
for 6 d
1200 mg dose
administered by IV
once
CUTI: 1.5 g every 8 h
for 7 d
CIAI:1.5 g every 8 h
for 4–14 d
CUTI: 2.5 g every 8 h
for 7–14 d

Fidaxomicin

Dalbavancin

Tedizolid

342.00

99.60

Oral: 354.00
IV: 282.00
1160.00

1788.00

191.49

198.46

166.63

AWP Unit
Price, $*

2.5 g

1.5 g

400 mg

200 mg

500 mg

100 mg

200 mg

600 mg

Unit

CIAI: 5130–14 364

CIAI: Meropenem

CUTI:
Imipenem–
cilastatin

CIAI: Meropenem

CUTI: 7182–14 364

CUTI: Levoﬂoxacin

CIAI: 1195.20–4183.20

Vancomycin

Linezolid

Placebo (both
groups received
a background
multidrug
anti–TB treatment
regimen)
Vancomycin or
linezolid

CUTI: 2091.60

Oral: 2124
IV: 1692
3480.00

5364.00

36 000.12

Vancomycin†

ABSSSI:
Vancomycin +
aztreonam

ABSSSI:
1666.30–4665.64
3969.20

CABP: Ceftriaxone

Drug

CABP: 1666.30–2332.82

Cost Range, $

CUTI: Levoﬂoxacin, 750
mg daily for 7 d
CIAI: Meropenem, 1 g
every 8 h for 4–10 d
CUTI: Imipenem–
cilastatin, 500 mg
every 6 h for 7–14 d
(optional switch to
ciproﬂoxacin after 4 d)
CIAI: Meropenem, 1 g
every 8 h for 5–14 d

Vancomycin, 1 g twice
daily for 3–14 d, with
optional switch to
linezolid, 600 mg twice
daily for 8 d
600 mg twice a day for
10 d
1 g every 12 h for 7–10 d

CABP: Ceftriaxone, 1 g
once daily for 5–7 d
ABSSSI: Vancomycin, 1 g
twice daily plus
aztreonam, 1 g twice
daily for 5–14 d
125-mg capsule 4 times
daily for 10 d
–‡

Dose and Duration

CIAI:12.85–70.37

CUTI: 12.60–30.00

CIAI: 12.85–70.37

CUTI: 0.05–0.10

7.47–20.52

183.67

Vancomycin:
7.47–20.52
Linezolid: 183.67

–‡

31.30–34.80

ABSSSI: vancomycin,
7.47–20.52;
aztreonam, 39.54

CABP: 1.80– 47.05

AWP Unit Price
Range, $*

Comparator

Meropenem, 1 g

Imipenem–cilastatin,
500 mg

Meropenem, 1 g

Levoﬂoxacin, 750 mg

1g

600 mg

Vancomycin, 1 g
Linezolid, 600 mg

–‡

125 mg

Vancomycin, 1 g,
plus aztreonam,
1g

Ceftriaxone, 1 g

Unit

CIAI: 192.75–2955.54

CUTI: 352.80–1680.00

CIAI: 154.20–2111.10

CUTI: 0.35–0.70

104.58–410.40

3673.40

Vancomycin: 44.82–574.56
Linezolid: 2938.72

–‡

1252.00–1392.00

ABSSSI: 470.10–1681.68

CABP: 9.00–329.35

Cost Range, $

CIAI: 27:1 to 5:1

CUTI: 20:1 to 9:1

CUTI: 5976:1 to
2988:1
CIAI: 8:1 to 2:1

Oral 0.5:1
IV 0.5:1
33:1 to 9:1

Vancomycin: 120:1
to 9:1
Linezolid: 2:1

–‡

3:1

ABSSSI: 4:1 to 3:1

CABP: 185:1 to 7:1

Cost Ratio

ABSSSI = acute bacterial skin and skin-structure infection; AWP = average wholesale price; CABP = community-acquired bacterial pneumonia; CIAI = complicated intra-abdominal infection;
CUTI = complicated urinary tract infection; IV = intravenous; MTZ = metronidazole; TB = tuberculosis.
† Although the ﬁdaxomicin trials used oral vancomycin (cost shown here), some hospitals may compound generic IV into oral capsules, greatly reducing the cost.
‡ Background multidrug anti-TB regimen varied by individual. Possible drugs included ethionamide, kanamycin, oﬂoxacin, pyrazinamide, and terizidine (all off-patent).

Ceftazidime–
avibactam

Ceftolozane–
tazobactam

Oritavancin

CIAI: 2.5 g every 8 h
for 5–14 d + MTZ

CABP: 600 mg every
12 h for 5–7 d
ABSSSI: 600 mg
every 12 h for
5–14 d

Ceftaroline

Bedaquiline

Dose and Duration

Drug

New Antibiotic

Appendix Table 2. Detailed Dose, Duration, and Cost of Antibiotic Drugs and Trial Comparators

